AbbVie has completed its $1.4-billion acquisition of Aliada Therapeutics, a bio/pharmaceutical company focused on central nervous system (CNS) diseases, for $1.4 billion. The companies had announced the acquisition in October (October 2024).  

Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody for treating Alzheimer’s disease, currently in Phase I development.   

Aliada has a proprietary platform engineered for CNS drugs to enable drug delivery across the blood–brain barrier (BBB). Its BBB-crossing technology targets transferrin and CD98 receptors (TfR and CD98), which are highly expressed in brain endothelial cells, according to information from AbbVie. By engineering highly optimized TfR or CD98 binders, this platform is designed to deliver different types of biological cargoes into the brain, including therapeutic antibodies and genetic medicines such as siRNA. 

Source: AbbVie